Cansino Biologics Inc (688185) — Capital Reinvestment Ratio

Latest as of September 2025: 1.45x

Cansino Biologics Inc (688185) has a Capital Reinvestment Ratio of 1.45x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥30.53 Million) in capital expenditures (CN¥44.23 Million). Check 688185 tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

1.45x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥30.53 Million
CNY

Capital Expenditures

CN¥44.23 Million
CNY

Data as of

Sep 2025
Most recent filing

Cansino Biologics Inc Capital Reinvestment Ratio (2021–2025)

This chart tracks Cansino Biologics Inc's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see how efficiently does Cansino Biologics Inc generate cash.

Annual Capital Reinvestment Ratio for Cansino Biologics Inc (2021–2025)

Year-by-year Capital Reinvestment Ratio for Cansino Biologics Inc from 2021 to 2025. See Cansino Biologics Inc (688185) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 3.13x CN¥77.86 Million CN¥243.90 Million ▲ +424.5%
2021 0.60x CN¥2.01 Billion CN¥1.20 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow